Telemedicine or video conferencing in lieu of face-to-face meetings could become an invaluable part of the standard Alzheimer’s disease (AD) care regimen in the future.
The value of using telemedicine is especially great for patients who live in rural areas, patients who have difficulties in travelling to a specialist’s medical office, and patients who have chronic diseases that require frequent assessments over many years.
Many AD patients face such challenges, making them ideal candidates to benefit from this tool. GlobalData’s epidemiology analysis reports that there are 11.5 million total prevalent cases of AD in the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, Japan).
